# Quad-Agonist GLP Drugs for Pediatric Obesity: Future Perspectives

Canonical source: https://retacompare.com/research/quad-agonist-glp-drugs-for-pediatric-obesity

Therapeutic Applications · 2026-05-02


    This article explores the potential of next-generation quad-agonist GLP drugs for treating pediatric obesity, examining their mechanisms, pipeline status, and the ethical implications of their use in younger populations.


The big picture

As the landscape of obesity treatment evolves, the focus is shifting toward multi-agonist therapies that target multiple hormonal pathways. Following the promising Phase 3 trials of Retatrutide (LY3437943), a triple agonist of GLP-1, GIP, and glucagon, the pharmaceutical industry is increasingly interested in developing quad-agonist drugs. These therapies aim to enhance metabolic regulation and weight loss by simultaneously activating additional receptors, potentially improving outcomes for pediatric patients grappling with obesity. As the prevalence of obesity in children continues to rise, the need for effective pharmacological interventions becomes more pressing, highlighting the importance of exploring these next-generation therapies.


How it works

Multi-agonist therapies, particularly quad-agonists, are designed to engage multiple hormonal pathways involved in appetite regulation and energy metabolism. The mechanism of action typically involves the activation of GLP-1, GIP, and glucagon receptors, among others, which can synergistically enhance weight loss and improve metabolic profiles. For instance, GLP-1 agonists like Semaglutide and dual agonists like Tirzepatide have demonstrated efficacy in weight management by promoting satiety and enhancing insulin sensitivity. The theoretical addition of other agonistic pathways in quad-agonists could further amplify these effects, potentially leading to greater reductions in body weight and improvements in obesity-related comorbidities.


Key points at a glance

Retatrutide is a triple agonist currently in Phase 3 trials, targeting GLP-1, GIP, and glucagon.

Quad-agonist therapies are in early clinical stages, with no approved products available as of October 2023.

Multi-agonist drugs could offer enhanced efficacy in treating pediatric obesity compared to existing mono- or dual-agonist therapies.

Ethical considerations regarding the use of potent weight-loss medications in children are paramount.

Current studies on multi-agonists focus on metabolic outcomes and safety profiles.

Potential candidates in the pipeline include HM15275 from Hanmi and others in early development.

Long-term safety and efficacy data are essential for regulatory approval and clinical use.


Where this fits in the pipeline

The development of quad-agonist drugs is still in its infancy, with most candidates remaining in preclinical or early clinical stages (Phase 1/2). Companies such as Hanmi and Amgen are exploring various combinations of receptor targets, although specific details on efficacy and safety are limited. As of now, the landscape is characterized by ongoing research and development, with a focus on understanding the pharmacodynamics and pharmacokinetics of these complex therapies. The regulatory pathway for these drugs will require comprehensive data to ensure safety, especially in pediatric populations.


What it could mean for patients

If successfully developed and approved, quad-agonist therapies could significantly impact the management of pediatric obesity. The potential for enhanced metabolic control and weight loss could lead to improved overall health outcomes for children struggling with obesity. However, the clinical implications must be approached cautiously, considering the unique physiological and psychological aspects of pediatric patients. Long-term safety data will be crucial for determining the appropriateness of these therapies in younger populations, given the potential for adverse effects associated with potent pharmacological agents.


Open questions and what we don't yet know

Key uncertainties remain regarding the long-term safety and efficacy of quad-agonist therapies. Questions about the appropriate age for initiation, potential side effects, and the risk of developing tolerance or dependence are critical. Furthermore, the regulatory landscape for these novel agents will require careful navigation, as pediatric populations present unique challenges in drug approval processes. Ongoing studies will need to address these gaps to ensure that any future therapies are both safe and effective for children.


Bottom line

Quad-agonist therapies for pediatric obesity hold promise for enhanced metabolic control, but significant research and ethical considerations must be addressed before they can be integrated into clinical practice.


This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources